US/UK/Canada

Share

Contacts

  • Erik Frick

    CEO


    Medicon Village SE-223 81 LUND, Sweden Visiting address: Scheeletorget 1
    +46736612123
    http://www.paindrainer.com
    • Pick a time period -
    Tags ( Active)

    Paindrainer AB joins forces with Libertas Medical Services to strengthen their patient offering within Pain

    Paindrainer AB is pleased to announce a commercial partnership agreement with Libertas Medical Services, a premier care provider located in Clifton Park, focusing on treating patient with Chronic pain. This collaboration marks a significant milestone in Paindrainer's mission to revolutionize chronic pain management and expand its presence in the U.S. healthcare market.Paindrainer AB persistently focus to achieve an increased presence in the US, now resulting in a new partnership with great potential. Paindrainer’s innovative Remote Therapeutic Monitoring (RTM) solution, designed to

    Paindrainer AB Achieves SOC 2 Type 1 Attestation, Reinforcing Commitment to Data Security in Digital Pain Management

    LUND, SWEDEN – Paindrainer AB is proud to announce that the company now has successfully achieved SOC 2 Type 1 attestation for its medical device, PD Care System. This milestone underscores Paindrainer’s commitment to protecting partner and patient data by meeting the highest standards of data security in digital health.The SOC2 attestation is a voluntary yet highly important compliance review set forth by the American Institute of Certified Public Accountants (AICPA), which include data security, availability, confidentiality, processing integrity and privacy. The audit, focusing on data

    Region Skåne initiate User Study with Paindrainer AB’s Unique Digital medical device for Patient-Centred Pain Management

    LUND, SWEDEN – Paindrainer AB, a pioneer in digital healthcare, is participating in a user study in collaboration with Region Skåne and Lund University. The study is being conducted within Region Skåne’s primary care system, aiming to strengthen care processes, improve treatment outcomes, and enhance the quality of life for patients living with chronic pain.Paindrainer® offers an advanced digital solution through its PD Care system, consisting of a PD Care portal and an PD Care mobile application. These tools enable healthcare professionals to remotely monitor patient progress in a

    Paindrainer AB raises 9.5 million in an oversubscribed share issue

    LUND, SWEDEN – Paindrainer AB announces a successfully completed share issue of 9.5 MSEK, supported by Almi Invest, Fredrik Sjödin via Tramontane Invest, ReThink Capital and existing shareholders.The use of proceeds focuses on Paindrainer AB continued successful commercial rollout in the US of the unique drug-free, digital remote therapeutic monitoring system for chronic pain patients, using a proprietary AI powered neural network.  It also enables the company to continue conducting clinical trials with top-tier health organizations, as well as to add further functionalities to the digital

    Paindrainer AB partners with Complete Care Partners LLC to accelerate the commercial role out in U.S. and transform chronic pain management

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB announces that the company has signed a partnership agreement allowing access to several thousand patients with chronic conditions managed by Complete Care Partner (CCP). This is made possible since Complete Care Partners (CCP) will access Paindrainer PD1, the company’s complete solution for Remote Therapeutic Monitoring (RTM), in their services reaching patients in over 70 healthcare providers.Paindrainer's RTM solution, designed to improve chronic pain management and eligible for reimbursement, is already used in private pain clinics. The

    Paindrainer AB shortlisted for prominent Life Science Awards at NLSDays 2024

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB, is proud to be selected as one of few companies shortlisted for the esteemed Nordic Star pitch competition. This prestigious pitch competition will take place at Nordic Life Science Days (NLSDays) in Malmö, Sweden on September 18-19, 2024.NLSDays, the premier Nordic life science event, has curated a competitive shortlist of small- and medium-sized private companies excelling in research and development. Paindrainer AB’s inclusion in this list highlights its groundbreaking work in developing AI-powered innovative and evidence-based solutions

    Paindrainer AB is selected to the prestigious Prevent2Care Program upheld by Ramsay Santé Foundation and Pfizer Innovation France

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB, is pleased to announce its selection for the prestigious Prevent2Care Lab Program. This program provides invaluable access to the extensive business expertise of the Ramsay Santé Group, a European leader in the private hospitalization, embodying their commitment to innovation.Initiated by the Ramsay Santé Foundation and backed by Pfizer Innovation France, the Prevent2Care Lab is dedicated to supporting innovative solutions in the field of preventive healthcare. In collaboration with the regional structures – Capio in Sweden and Denmark, and

    Paindrainer’s digital medical device approved for a clinical study investigating its effect on brain activities

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB is pleased to announce the approval of a clinical study of the effect of Paindrainer's digital medical device on brain activities.The Paindrainer digital medical device will be used to investigate how chronic pain is processed in the brain using Cleveland Clinic’s established brain scanning technology, as well as evaluate the correlation between users' logged data and objectively measured real world data through wearables. The study will be held at Cleveland Clinic in collaboration with Lund University. “It is a unique opportunity and very

    Paindrainer’s digital medical device approved for a clinical study investigating its effect on brain activities

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB is pleased to announce the approval of a clinical study of the effect of Paindrainer's digital medical device on brain activities.The Paindrainer digital medical device will be used to investigate how chronic pain is processed in the brain using Cleveland Clinic’s established brain scanning technology, as well as evaluate the correlation between users' logged data and objectively measured real world data through wearables. The study will be held at Cleveland Clinic in collaboration with Lund University. “It is a unique opportunity and very

    Paindrainer AB to be granted patent for its unique patient-centric concept for chronic pain management

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB, a pioneer in the field of digital healthcare technology, is pleased to announce that the European Patent Office (EPO) has granted a patent for its unique proprietary platform for 360° patient-centricity, chronic pain management, powered by an artificial neural network.At its core, this patent outlines a personalized pain-management platform that leverages users’ own data and a neural network analysis to provide tailored recommendations. These recommendations are fully adaptive to each user, aiming to alleviate pain and enhance quality of life

    Paindrainer AB announces novel partnership with esteemed Bragée Clinics to enhance remote patient care through patient-centric digital pain management programs

    MEDICON VILLAGE, LUND, SWEDEN – Under a new partnership, Paindrainer AB, a pioneer in the field of digital healthcare technology and the well-established Bragée Clinics will conduct a commercial pilot aimed at strengthening pain management programs for remote chronic pain rehabilitation and treatment programs.Paindrainer offers an advanced digital solution in Paindrainer® Care Portal and evidence based Paindrainer® PD1 mobile application for health care professionals to remotely monitor their patients’ progress and improve their quality of life. Bragée Clinics is a premier clinic

    Paindrainer AB launches a pioneering Remote Therapeutic Monitoring (RTM) platform for innovative chronic pain management

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB, a forerunner in digital medical device solutions for chronic pain, is pleased to introduce the Paindrainer Care Portal, which together with the Paindrainer PD1 mobile application offers a complete solution for health care professionals to remotely monitor their patients’ progress and improve their quality of life.The utilization of a remote therapeutic monitoring platform will provide health care professionals with important insights into how the daily routines affects the health of their patients. This will facilitate the creation of improved

    Paindrainer AB selected for the groundbreaking 10XHEALTH Scaleup Program with a focus to accelerate growth in Swedish Life Science companies

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB, a pioneer in digital medical device solutions for chronic pain, is proud to announce to been selected as one of seven prestigious participants in the inaugural 10XHEALTH program, a collaborative initiative by SmiLe Incubator and Medicon Village. The program is set to be launched in January 2024, with the aim of propelling established life science companies in Southern Sweden toward accelerated international growth.Paindrainer® is the first evidence based digital tool demonstrating improved quality of life in patients suffering from chronic

    Paindrainer AB enters the U.S. market by successfully securing its first commercial partnership

    Paindrainer AB is pleased to announce the formalization of a commercial partnership agreement with Dr. Edward Rubin, Past President of The New York Society of Interventional Pain Physicians. This strategic collaboration accomplishes a crucial milestone, allowing Paindrainer AB access to the U.S. market with its groundbreaking FDA registered Medical Device Class I digital solution for chronic pain management.Paindrainer AB has persistently focused to achieve an increased presence in the US, now resulting in this crucial strategic milestone securing the entry into the American market. ”I

    Paindrainer AB and IHE publish US Health Economic Study highlighting excessive cost to society and payers for chronic pain

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB, in collaboration with the Institute of Health Economics (IHE), has undertaken and unveiled considerable costs in a health economic study. The study underscores the substantial impact of chronic pain on the cost to both society, health organisations and payers. In addition, it also sheds light on the potential for improvement through the utilization of a digital self-management tool like Paindrainer®.The main outcomes of the study are: · Chronic pain is associated with a significant burden, including a low quality-of-life, significant

    Paindrainer AB and the Swedish Association of Fibromyalgia has signed an agreement offering their members the novel digital coach for improved quality of life

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB is pleased to announce that the company has signed a commercial agreement with the Swedish Fibromyalgia Association, offering Paindrainer® as a complimentary membership benefit.The Swedish Association of Fibromyalgia has been participating in the development of Paindrainer®, ensuring the creation of a user-friendly digital tool that adds value to the everyday life of those living with chronic pain. The agreement allows the association to actively promote Paindrainer as a membership benefit to enhance its position as a patient organization and

    Massive Entertainment expands its collaboration with the local health-tech company Paindrainer AB

    LUND, SWEDEN – Paindrainer AB and Malmö based gaming studio Massive Entertainment – a Ubisoft Studio, has been collaborating in the development of the evidence-based Paindrainer® app, since 2020. The companies have now reached the stage where a joint pilot test program for the employees of Massive Entertainment will be initiated.With this strengthen collaboration Paindrainer will expand the reach into company employees suffering from chronic pain. Simultaneously, the collaboration provides valuable insights of how to further scale operations into companies with sustainable and responsible

    Paindrainer® secures certification by ORCHA – the world’s leading digital health evaluation organization

    LUND, SWEDEN – The company is pleased to announce that the Paindrainer® App has been certified by the Organization for the Review of Care and Health Apps (ORCHA). ORCHA is the world’s leading, independent digital health evaluation and distribution organization, providing verification and certification, which is trusted and accepted by health-care organizations internationally.ORCHA’s assessment involves a detailed analysis looking across all the key areas of regulation and compliance. Mobile health apps are assessed against 350 criteria covering 3 main domains: · Clinical assurance and

    Paindrainer® wins the prestigious Nordic Health App Award 2023

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB is proud to announce that the company’s 360° patient-centric[©] app Paindrainer® was announced as the winner of the Nordic Health App Award 2023 at the “Arendalsuka” in Norway.Nordic Innovation is an organization under the Nordic Council of Ministers. Their overall aim is that the Nordics will be the most sustainable and integrated health region in the world by 2030, providing the best possible personalized health care for all its citizens. Aligned with this aim, Nordic Innovation launched the Nordic Health App Award 2023 to discover and

    Paindrainer AB´s digital tool is the first device targeting chronic pain to receive FDA registration approval as a Medical Device Class 1

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB is pleased to announce that the company’s 360° patient-centric[©] app (Paindrainer® PD1) has received registration approval as a Medical Device Class 1 (510k exemption) by the U.S. Food and Drug Administration (FDA).A Medical Device Class 1 falls under the low risk category according to the FDA classification system, which was also in line with the absent of risk observed in the most recent multi-center trial in the US. "We are thrilled to share this significant achievement and milestone that the Paindrainer® App, as the first self-

    Paindrainer´s clinical multi-center study shows remarkable positive improvements for chronic pain patients

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB announces the publication of its pivotal multi-center study in the well-respected Pain Medicine, the official journal of American Academy of Pain Medicine. The study clearly demonstrates that self-management of chronic pain using Paindrainer´s digital tool, powered by a proprietary neural network, significantly improved subjects’ pain interference, physical function, depression, anxiety, and pain catastrophizing over the 12-week study period.The pivotal multi-center study conducted with Newton-Wellesley Hospital and Weill Cornell Medicine was

    Paindrainer´s clinical multi-center study shows remarkable positive improvements for chronic pain patients

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB announces the publication of its pivotal multi-center study in the well-respected journal Pain Medicine. The study clearly demonstrates that self-management of chronic pain using Paindrainer´s digital tool, powered by a proprietary neural network, significantly improved subjects’ pain interference, physical function, depression, anxiety, and pain catastrophizing over the 12-week study period.The pivotal multi-center study conducted with Newton-Wellesley Hospital and Weill Cornell Medicine was successfully completed and published in the leading

    Paindrainer´s clinical multi-center study shows remarkable positive improvements for chronic pain patients

    MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB announces the publication of its pivotal multi-center study in the well-respected journal Pain Medicine. The study clearly demonstrates that self-management of chronic pain using Paindrainer´s digital tool, powered by a proprietary AI-neural network, significantly improved subjects’ pain interference, physical function, depression, anxiety, and pain catastrophizing over the 12-week study period.The pivotal multi-center study conducted with Newton-Wellesley Hospital and Weill Cornell Medicine is successfully completed and published in the

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media